1-5 of 5
Yong Hao, PhD
Close
Sort by
Journal Articles

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L. Kropf, MD, Karen W.L. Yee, MD, Casey L. O'Connell, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Nikolai A. Podeltsev, MD, Elizabeth A. Griffiths, MD, Elias Jabbour, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Wendy Stock, MD, Michael R. Savona, MD, Todd L. Rosenblat, MD MS, Jesus G. Berdeja, MD, Laksmi Wilson, James N. Lowder, MD, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2015) 126 (23): 458.
https://doi.org/10.1182/blood.V126.23.458.458
Published: 2015
Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine Walsh, MD, Michael Savona, MD, Patricia Kropf, MD, Casey O'Connell, MD, Raoul Tibes, MD, Naval G. Daver, MD, Elias Jabbour, MD, Scott Lunin, MD, Todd L. Rosenblat, MD, Karen Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph R Mace, MD, Nikolai A. Podoltsev, MDPhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2014) 124 (21): 529.
https://doi.org/10.1182/blood.V124.21.529.529
Published: 2014
Journal Articles

Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study

Woonbok Chung, PhD, Pietro Taverna, PhD, John F Lyons, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Patricia Kropf, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 1442.
https://doi.org/10.1182/blood.V122.21.1442.1442
Published: 2013
Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Gail J. Roboz, MD, Jean-Pierre Issa, MD, David Rizzieri, MD, Wendy Stock, MD, Casey O'Connell, MD, Karen Yee, MD, Raoul Tibes, MD, Elizabeth A. Griffiths, MD, Katherine Walsh, MD, Eric J. Feldman, MD, Ellen Ritchie, MD, Arati V. Rao, MD, Richard A. Larson, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD, Aaron Schimmer, PhD, MD, Ruben A. Mesa, MD, William Blum, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Gavin Choy, PharmD, Mohammad Azab, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 1548.
https://doi.org/10.1182/blood.V122.21.1548.1548
Published: 2013
Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Karen Yee, MD, Patricia Kropf, MD, Casey O'Connell, MD, Wendy Stock, MD, Raoul Tibes, MD, PhD, David Rizzieri, MD, Katherine Walsh, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Michael Savona, MD, Thomas Ervin, MD, Nikolai A. Podoltsev, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Joseph M. Brandwein, MD, Olatoyosi Odenike, MBBS, Eric J. Feldman, MD, Woonbok Chung, PhD, Sue Naim, Gavin Choy, PharmD, Pietro Taverna, PhD, Yong Hao, PhD, George Dimitrov, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 497.
https://doi.org/10.1182/blood.V122.21.497.497
Published: 2013